car-t cell toxicity management
Why CAR-T Safety May Already Need a Rewrite
In 2023, the CASTLE basket trial reported that cytopenias were the most common adverse event, highlighting a safety gap for CAR-T in autoimmune disease. The trial’s deep B-cell depletion came at the cost of prolonged, low-grade marrow suppression, which is untenable for fragile, treatment-refractory patients. Medical Disclaimer: This article